

OUTCOMES

TCC/Urothelial Carcinoma

Targeted therapy offers additional MST for dogs with TCC.

A combination of two targeted therapies plus traditional chemotherapy showed survival benefit compared to published MST with piroxicam alone.


An independent published research from the University of Tokyo shows similar success with targeted therapies as first line treatment for TCC.

FidoCure® Preliminary TCC Data	
Piroxicam alone	Lapatinib + trametinib + chemo
MST 216* days	MST 425.5 days
* Maeda et al., 2022	

	Piroxicam	Mitoxantrone	Carboplatin	Vinblastine
# of dogs	n=42	n=26	n=24	n=28
Median Survival Time (days)	216	247.5	263	299

Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs

Maeda, S., Sakai, K., Kaji, K. et al. *Sci Rep* 12, 4 (2022). Nature, January 2022



Maeda et al., 2022 Lapatinib

T2NOMO + lapatinib T3NOMO + lapatinib

MST 409 days

MST 390 days

P = 0.0001 compared to Piroxicam only